Funding for this research was provided by:
Received: 28 January 2020
Accepted: 11 June 2020
First Online: 16 June 2020
Ethics approval and consent to participate
: The study protocol was approved by the regional Ethics Committee and patients included in this study gave their written informed consent before any study related procedures were conducted.
: H. Sorbye: Ipsen, Novartis and Pfizer (consultant, honoraria and research funding). E. Thiis-Evensen: Ipsen, Novartis and Pfizer (honoraria and research funding). Simen Myhre is an employee (Medical Advisor) of Novartis Oncology Norway. For the remaining authors, no conflicts of interest were declared.